{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1381699993621246342.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Michael Millward"}],"foaf:familyName":[{"@value":"Millward"}],"foaf:givenName":[{"@value":"Michael"}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1361699993621246592","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1016/s1470-2045(20)30494-0"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1470204520304940?httpAccept=text/xml"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1470204520304940?httpAccept=text/plain"}],"notation":[{"@value":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/s1470-2045(20)30494-0_Lm9apqVvHyq6dSwd7lHNRTElzb3"}]}